<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Surgical resection of hepatocellular carcinoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Surgical resection of hepatocellular carcinoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Surgical resection of hepatocellular carcinoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven A Curley, MD, FACS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carlton C Barnett, Jr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eddie K Abdalla, MD, FACS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stanley W Ashley, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth K Tanabe, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wenliang Chen, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hepatocellular carcinoma (HCC) is a tumor with highly variable biology that often occurs in the setting of chronic liver disease and cirrhosis. When not detected through screening, it is typically diagnosed late in its course, and the median survival following diagnosis is approximately 6 to 20 months [<a href="#rid1">1</a>]. The mainstay of potentially curative treatment for HCC is surgical resection, but several other treatment modalities may also have a role. </p><p>Surgical resection of HCC will be reviewed here. The clinical manifestations and diagnosis of HCC, an overview of the treatment approach to HCC, nonsurgical local ablative options, liver transplantation, and adjuvant and neoadjuvant therapy are reviewed elsewhere. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3599.html" rel="external">"Epidemiology and risk factors for hepatocellular carcinoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">"Overview of treatment approaches for hepatocellular carcinoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2487.html" rel="external">"Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates who are eligible for local ablation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15589.html" rel="external">"Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates not eligible for local thermal ablation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2490.html" rel="external">"Liver transplantation for hepatocellular carcinoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/17215.html" rel="external">"Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">TREATMENT ALGORITHMS FOR HCC</span><span class="headingEndMark"> — </span>A general approach to treatment of HCC is shown in the algorithm  (<a class="graphic graphic_algorithm graphicRef57014" href="/z/d/graphic/57014.html" rel="external">algorithm 1</a>). The suggested approach is useful for conceptualizing the various treatment options that are available for individual patients but may not be applicable in all settings. An alternative approach, the Barcelona Clinic Liver Cancer (BCLC) staging system, has been a dominant approach to HCC internationally. There are five stages based on the extent of the primary lesion, performance status, vascular invasion, and extrahepatic spread; this classification was updated in 2022  (<a class="graphic graphic_figure graphicRef139139" href="/z/d/graphic/139139.html" rel="external">figure 1</a>) [<a href="#rid2">2</a>]. Yet another alternative approach is widely used in the Asia-Pacific region where HCC is prevalent [<a href="#rid3">3</a>]. An overview of available therapies for HCC are summarized elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">"Overview of treatment approaches for hepatocellular carcinoma", section on 'Treatment algorithms'</a>.)</p><p class="headingAnchor" id="H1041709280"><span class="h2">Treatment options for surgical candidates</span><span class="headingEndMark"> — </span>Surgery (liver resection and transplantation) offers long-term survival with good quality of life and is the only potential cure for large HCCs.</p><p>Patients ideally suited for liver resection have localized HCC confined to the liver without radiographic evidence of invasion of the vasculature of the liver  (<a class="graphic graphic_diagnosticimage graphicRef54856" href="/z/d/graphic/54856.html" rel="external">image 1</a>), preserved hepatic function, and no evidence of portal hypertension (although a minor resection could be considered in some patients with portal hypertension) [<a href="#rid4">4-6</a>]. Resection can provide benefits for some patients with multifocal disease or those with major vascular invasion, although outcomes are less favorable [<a href="#rid7">7,8</a>]. (See  <a class="medical medical_review" href="/z/d/html/2476.html" rel="external">"Staging and prognostic factors in hepatocellular carcinoma", section on 'Clinical implications'</a>.)</p><p>Despite even aggressive surgical approaches, most patients have disease (either HCC or underlying chronic liver disease) that is too extensive to permit treatment with "curative" intent. In high-incidence regions of the world, only 10 to 15 percent of newly diagnosed patients are candidates for standard resection, whereas in low-incidence areas, between 15 and 30 percent of patients have potentially resectable disease [<a href="#rid9">9-11</a>]. (See  <a class="medical medical_review" href="/z/d/html/3599.html" rel="external">"Epidemiology and risk factors for hepatocellular carcinoma"</a>.)</p><p>Surgical candidates who have early HCC and underlying liver disease are increasingly being considered for transplantation because of potential for better disease-free survival and resolution of underlying liver disease, though this approach is limited by organ availability, especially in resectable patients. (See  <a class="medical medical_review" href="/z/d/html/2490.html" rel="external">"Liver transplantation for hepatocellular carcinoma"</a>.)</p><p class="headingAnchor" id="H1719631715"><span class="h2">Treatment options for nonsurgical candidates</span><span class="headingEndMark"> — </span>For patients with liver-confined HCC who are not candidates for standard resection, alternative treatment modalities include interstitial therapies; transarterial chemoembolization; transarterial radioembolization (embolization with particles emitting radiation); localized ablative techniques involving either cryoablation, chemical desiccation (eg, ethanol or acetic acid ablation), or heating with laser; microwave, or radiofrequency ablation. These nonsurgical local ablative treatments are discussed elsewhere. These approaches are used as definitive therapies as well as bridging or downstaging therapy to liver transplantation. (See  <a class="medical medical_review" href="/z/d/html/2487.html" rel="external">"Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates who are eligible for local ablation"</a> and  <a class="medical medical_review" href="/z/d/html/15589.html" rel="external">"Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates not eligible for local thermal ablation"</a>.)</p><p class="headingAnchor" id="H457344296"><span class="h1">IMPORTANCE OF COMPREHENSIVE MULTIDISCIPLINARY CARE</span><span class="headingEndMark"> — </span>A majority of patients with HCC have an underlying liver disease, such as hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection (more common in the United States), or metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver diseases (NAFLD) [<a href="#rid12">12</a>]. Management of MASLD is particularly challenging because many patients have concomitant viral hepatitis in addition to obesity [<a href="#rid13">13-16</a>].</p><p>Furthermore, patients with chronic liver disease who undergo any form of therapy for HCC are at high risk for recurrent disease and progression to liver failure. It is important that patients with more advanced liver disease have proper monitoring and assessment of their underlying liver disease, which may have a major impact on longer-term survival. </p><p>The wide variety of treatments for HCC are offered by different specialties: surgery, transplant hepatology, interventional radiology, radiation oncology, and medical oncology. Multidisciplinary evaluation, planning, and management are frequently coordinated by hepatologists and improves patient outcomes [<a href="#rid17">17</a>]. </p><p class="headingAnchor" id="H4"><span class="h1">PREOPERATIVE ASSESSMENT FOR RESECTABILITY</span><span class="headingEndMark"> — </span>Only one-half of patients initially thought to be resectable and referred for surgery actually have resectable tumors. Among the reasons for unresectability are the extent of intrahepatic disease, extrahepatic extension, inadequate functional hepatic reserve, and involvement of the confluence of the portal or hepatic veins [<a href="#rid9">9,18</a>]. The assessment of potential resectability of HCC focuses on two main issues: </p><p class="bulletIndent1"><span class="glyph">●</span>The likelihood of the disease being confined to the liver (except fibrolamellar subtype of HCC). (See  <a class="medical medical_review" href="/z/d/html/16571.html" rel="external">"Epidemiology, clinical manifestations, diagnosis, and treatment of fibrolamellar carcinoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Whether the size and location of the tumor/extent of liver resection required relative to the patient's underlying liver function will permit resection without excess morbidity and mortality. </p><p></p><p>There is no general rule regarding tumor location, size, or number in selecting patients with HCC for resection; however, most consider stage IIIB, IVA, and IVB disease to be incurable by resection  (<a class="graphic graphic_table graphicRef110835" href="/z/d/graphic/110835.html" rel="external">table 1</a>). These stages are defined by invasion of a major portal or hepatic vein, direct invasion of organs other than the gallbladder, perforation of the visceral peritoneum (IIIB), and nodal (IVA) or distant metastases (IVB). However, hepatic resection for stage IIIB and IVA disease may be considered in a center of excellence because clinical benefits and long-term survival can be achieved in a properly selected, though admittedly small, minority of patients. Such resections are often considered only after neoadjuvant therapy.</p><p class="headingAnchor" id="H911044863"><span class="h2">Exclude extrahepatic metastasis</span><span class="headingEndMark"> — </span>The recognized sites of metastatic spread of HCC are lung, bone, peritoneum, and adrenals [<a href="#rid19">19</a>]. For patients being evaluated for surgical resection, we suggest excluding pulmonary metastasis with a chest computed tomography (CT) with contrast if liver transplant is considered, excluding bone metastasis with a bone scan in patients with skeletal symptoms, and excluding peritoneal metastasis with a diagnostic laparoscopy if there are high risk features.</p><p>In patients who have localized HCC, the rate of extrahepatic disease spread at diagnosis is overall low, and staging chest CT and bone scans do not provide additional information on metastases. The utility of 18-fluorodeoxyglucose positive emission tomography scanning for detection of otherwise occult distant metastatic disease is uncertain and not recommended in guidelines from the National Comprehensive Cancer Network (NCCN) [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma", section on 'Evaluation after HCC Diagnosis'</a>.)</p><p>However, the risk of extrahepatic metastatic disease is higher in patients with a tumor that is large (&gt;5 cm), is located at a subdiaphragmatic location, demonstrates vascular invasion, or is associated with markedly elevated alpha-fetoprotein. Patients who have such tumors warrant additional imaging studies or diagnostic laparoscopy prior to resection, particularly if they have worrisome symptoms such as bone pain. (See  <a class="medical medical_review" href="/z/d/html/15106.html" rel="external">"Diagnostic staging laparoscopy for digestive system cancers", section on 'Hepatocellular carcinoma'</a>.)</p><p>Although other sites of disease may be demonstrated by standard imaging techniques, peritoneal disease is frequently missed. Laparoscopy and intraoperative ultrasound (IOUS) may improve the selection of patients for potentially curative resection [<a href="#rid21">21</a>]. IOUS can accurately determine the size of the primary tumor and detect lymph node or portal or hepatic vein involvement, which precludes curative resection [<a href="#rid22">22,23</a>]. Another benefit of IOUS is the identification of major intrahepatic vascular structures, which can be used to guide segmental or nonanatomic resections [<a href="#rid24">24</a>]. However, IOUS can be difficult to interpret, and findings may be nonspecific in patients with regenerative nodules in more advanced cirrhosis. (See  <a class="medical medical_review" href="/z/d/html/15106.html" rel="external">"Diagnostic staging laparoscopy for digestive system cancers", section on 'Laparoscopic ultrasound'</a>.)</p><p class="headingAnchor" id="H2109304681"><span class="h2">Exclude portal lymph node metastasis</span><span class="headingEndMark"> — </span>Although practice is variable [<a href="#rid25">25-28</a>], we consider that documented regional (portal) nodal involvement precludes potentially curative resection for HCC. However, lymph node involvement is <strong>not</strong> a contraindication to resection for patients with fibrolamellar HCC; these patients undergo a formal lymph node dissection. (See  <a class="medical medical_review" href="/z/d/html/16571.html" rel="external">"Epidemiology, clinical manifestations, diagnosis, and treatment of fibrolamellar carcinoma", section on 'Potentially resectable disease'</a>.)</p><p>Lymph node metastases are uncommon overall (between 1 and 8 percent), but their presence portends a worse outcome [<a href="#rid29">29,30</a>]. Preoperative detection of nodal metastases is limited by the frequent presence of benign nodal enlargement, most often involving the porta hepatis and portacaval space, in patients with cirrhosis [<a href="#rid31">31</a>]. Highly suspicious nodes based on enhancement similar to the intrahepatic HCC lesions indicate the need for biopsy in a patient being considered for resection [<a href="#rid32">32</a>]. Outcomes are worse in patients who have regional nodal involvement. </p><p class="headingAnchor" id="H6"><span class="h2">Delineate tumor extent</span><span class="headingEndMark"> — </span>For patients being evaluated for surgical resection, we suggest assessing tumor extent with either a multiphase CT (including arterial phase) or an MRI of the abdomen and pelvis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CT</strong> – Anatomic delineation of tumor extent is best achieved with dynamic multiphase CT, for which the nonenhanced, hepatic arterial phase is assessed separately from the portal venous phase and a late "wash-out" phase. Small HCCs are often isodense to the liver in the portal venous phase and may be missed on a conventional "screening" CT [<a href="#rid33">33</a>]. In contrast, arterial phase imaging detects 30 to 40 percent more tumor nodules than conventional CT and may be the only phase needed to demonstrate the tumor in 7 to 10 percent of cases [<a href="#rid34">34,35</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MRI</strong> – Magnetic resonance imaging (MRI) appears to be as accurate, or more accurate, than CT in liver staging for HCC using both multiphasic and multiparametric imaging (combining T1, T2, and diffusion-weighted imaging with dynamic multiphasic imaging). Several studies have shown MRI to be superior to CT for detection of HCC, particularly in cirrhotic livers and particularly for correct diagnosis of smaller nodules [<a href="#rid36">36-38</a>]. MRI with hepatocyte-specific contrast agents (eg, gadolinium-based agents such as Gd-BOPTA and Gd-EOB-DTPA) may increase lesion detection, improve lesion characterization, and may be useful in the detection of recurrence as well [<a href="#rid39">39-41</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Others</strong> – The role of other imaging studies in the evaluation of primary HCC, including positron emission tomography with conventional and novel agents and CT arteriography, is discussed in detail elsewhere. In general, these studies add little to thin-slice, multiphasic imaging except in highly selected cases or for detecting metastatic diseases (eg, to lymph nodes or bone). (See  <a class="medical medical_review" href="/z/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma", section on 'Evaluation after HCC Diagnosis'</a>.)</p><p></p><p class="headingAnchor" id="H801426564"><span class="h2">Determine resectability based on tumor extent</span><span class="headingEndMark"> — </span>Advances in the surgical management of HCC have expanded the indications for curative hepatectomy, including more extensive liver resections [<a href="#rid42">42</a>]. The impact of size, multifocality, and tumor rupture on resectability is debated; there is no general internationally accepted consensus regarding tumor location, size, or number in selecting patients with HCC for resection. (See  <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">"Overview of treatment approaches for hepatocellular carcinoma", section on 'Potentially resectable disease'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor size</strong> – Although some surgeons restrict eligibility for resection to patients with tumors that are ≤5 cm in diameter, most centers do not use size alone to select patients for resection [<a href="#rid7">7,43,44</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The likelihood of microvascular invasion increases with increasing tumor size. Patients with small tumors are less likely to harbor occult vascular invasion and have a better outcome after surgery. Patients with a solitary HCC without vascular invasion have a similar survival regardless of tumor size  (<a class="graphic graphic_figure graphicRef59785" href="/z/d/graphic/59785.html" rel="external">figure 2</a>) [<a href="#rid5">5,7,45-54</a>]. In the latest iteration of the American Joint Committee on Cancer (AJCC) staging system, T1 classification includes not only solitary tumors of any size without vascular invasion but also tumors ≤2 cm with or without microvascular invasion  (<a class="graphic graphic_table graphicRef110835" href="/z/d/graphic/110835.html" rel="external">table 1</a>) [<a href="#rid55">55</a>]. Although the presence and degree of vascular invasion portends increased risk for recurrence and is a powerful predictor of survival postresection, microvascular invasion in small tumors has a lesser impact on outcome and may be predicted from preoperative parameters [<a href="#rid56">56</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a multicenter retrospective review of 1115 patients with HCC, major hepatectomy was performed in 539 patients, for which the mean tumor size was 10 cm (range 1 to 27 cm) [<a href="#rid42">42</a>]. The tumor, node, metastasis (TNM) stage distribution was 29 percent stage I, 31 percent stage II, 38 percent stage III, and 2 percent stage IV. Five-year survival rates improved for each successive cohort at 30 percent for 1981 to 1989, 40 percent for 1990 to 1999, and 51 percent for 2000 to 2008. Perioperative mortality also improved. In multivariate analysis, factors significantly associated with worse outcomes included earlier time period, AFP level &gt;1000 ng/mL, tumor size &gt;5 cm, presence of major vascular invasion, presence of extrahepatic metastases, and positive surgical margins. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a prospective study of over 11,000 patients undergoing hepatectomy for HCC from 2002 to 2010 in Taiwan, patients with small (&lt;3 cm), medium (3 to 4.9 cm), large (5 to 10 cm), and huge (&gt;10 cm) tumors had five-year overall survival rates of 72, 62, 51, and 35 percent, and 10 year overall survival rates of 53, 42, 36, and &lt;20 percent, respectively [<a href="#rid57">57</a>]. Known factors that are predictive of poor outcomes, such as inadequate margins of resection, poor differentiation, multiple tumors, vascular invasion, and cirrhosis, also applied to patients with huge HCC. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a meta-analysis of 24 retrospective studies involving 3326 patients with HCC ≥10 cm and 20421 patients with smaller HCCs who underwent hepatectomy, HCC ≥10 cm was associate with both worse overall survival (hazard ratio [HR] 0.53, 95% CI 0.50-0.55) and disease-free survival (HR 0.62, 95% CI 0.58-0.84), although no significant difference was found for 30-day mortality rate (odds ratio [OR] 0.73, 95% CI 0.50-1.08), postoperative complications (OR 0.81, 95% CI 0.62-1.06), and posthepatectomy liver failure (OR 0.81, 95% CI 0.62-1.06) [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multiple tumors</strong> – Multifocality increases the T classification  (<a class="graphic graphic_table graphicRef110835" href="/z/d/graphic/110835.html" rel="external">table 1</a>) and is associated with lower survival but does not exclude a good outcome in selected patients [<a href="#rid59">59</a>]. In a systematic review, resection of multifocal HCC was associated with a median five-year survival of 49 percent (range 30 to 64) when up to three nodules were present, and 23 percent (range 0 to 54) in patients with more than three nodules [<a href="#rid60">60</a>]. </p><p></p><p class="bulletIndent1">Patients with multinodular HCC who appeared to benefit from resection were those with sufficient liver reserve to tolerate resection, without extrahepatic disease, and without major vascular invasion. Size alone is not a contraindication for resection of multinodular HCC. Unfortunately, many patients have multifocal disease that is underestimated even by high-quality CT and MRI. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor rupture</strong> – Approximately 10 percent of HCCs spontaneously rupture. The clinical picture is that of acute abdominal pain and distension, hypotension, and a drop in the hematocrit. Initially, these patients should be stabilized hemodynamically, followed by transarterial embolization for control of bleeding. If unsuccessful, emergency surgery may be required [<a href="#rid61">61</a>]. (See  <a class="medical medical_review" href="/z/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1">Although the presence of a tumor rupture suggests a high likelihood of peritoneal seeding and usually a poor outcome from resection, this is not inevitable [<a href="#rid62">62,63</a>]. If bleeding can be controlled with embolization, a formal staging evaluation should be undertaken, followed by laparoscopic exploration and a subsequent attempt at resection, if feasible [<a href="#rid64">64</a>]. Several retrospective series suggest a low but defined long-term survival rate following resection in such situations [<a href="#rid64">64-70</a>]. </p><p></p><p class="bulletIndent1">In a large retrospective study comparing ruptured versus nonruptured HCC that were resected, spontaneous rupture of HCC is not a risk factor for survival by multivariate analysis, and propensity-score matched patients with ruptured HCC (n = 156) had comparable five-year survival with those with unruptured HCC (n = 312, 44 versus 46 percent, p = 0.600) [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent1">Response of disease to neoadjuvant therapy is often used to help determine suitability for resection in these patients.</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Assessment of hepatic reserve</span><span class="headingEndMark"> — </span>Operative mortality for HCC is related to the severity of the underlying liver disease, being twice as high in cirrhotic as in noncirrhotic patients (10 versus 5 percent, respectively) [<a href="#rid72">72</a>]. As a general rule, patients who have complications of cirrhosis, such as bleeding, ascites, or marked portal hypertension, have insufficient hepatic reserve to withstand a partial hepatectomy, although there are exceptions [<a href="#rid73">73</a>]. </p><p>With proper patient selection, operative mortality, even in cirrhotic patients, should be low [<a href="#rid74">74-76</a>]. However, only approximately 20 to 30 percent of patients presenting with HCC will have adequate hepatic reserve to undergo resection [<a href="#rid77">77,78</a>]. </p><p>Hepatic reserve can be assessed by clinical tools, radiographic volumetry, functional test, or a combination of methods (eg, combined volumetric-functional assessment). The choice of methods is largely determined by their availability and locoregional preference, as some assessment is mandated by algorithms and guidelines [<a href="#rid79">79,80</a>]. </p><p class="headingAnchor" id="H3420738722"><span class="h3">Clinical scores</span><span class="headingEndMark"> — </span>Various clinical tools have been used to predict outcomes of liver resection based on baseline biochemical profiles of the patients. (See  <a class="medical medical_review" href="/z/d/html/2476.html" rel="external">"Staging and prognostic factors in hepatocellular carcinoma", section on 'Staging and prognostic scoring systems'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Child-Pugh class</strong> – In patients with cirrhosis, surgical resection is most safely performed in those with Child-Pugh class A disease  (<a class="graphic graphic_table graphicRef78401" href="/z/d/graphic/78401.html" rel="external">table 2</a>) who have a normal bilirubin level and well-preserved liver function. However, the Child-Pugh classification was not developed or validated in patients with HCC, and it provides too rough an estimate to allow accurate quantitative evaluation of the liver functional reserve or accurate prediction of the surgical risk in patients with liver dysfunction [<a href="#rid3">3</a>]. As an example, in one study of 29 such patients with HCC who underwent resection, 11 (38 percent) developed liver failure that was unresolved three months postoperatively due to increased portal pressure [<a href="#rid6">6</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MELD score</strong> – Another tool for assessing underlying liver disease, the Model for End-stage Liver Disease (MELD) score (<a class="calc calc_professional" href="/z/d/html/15636.html" rel="external">calculator 1</a>), was really intended for the transplant population. However, it is not useful to decide indication of resection, because it assesses only the degree of synthetic dysfunction but not the severity of portal hypertension. (See  <a class="medical medical_review" href="/z/d/html/1234.html" rel="external">"Assessing surgical risk in patients with liver disease", section on 'MELD score and Mayo risk score'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ALBI score</strong> – By contrast, the albumin-bilirubin (ALBI) score (<a class="calc calc_professional" href="/z/d/html/100996.html" rel="external">calculator 2</a>) may provide a simple, evidence-based, objective, and discriminatory method of assessing liver function in patients with HCC, and the use of the ALBI score may allow better refinement of prognostic estimates in patients with HCC across a wide spectrum of treatments, particularly among those with better liver function [<a href="#rid81">81-83</a>]. </p><p></p><p class="headingAnchor" id="H438261354"><span class="h3">Hepatic volumetry</span><span class="headingEndMark"> — </span>The volume and function of residual liver remnant can be determined using hepatic volumetry, which can be performed prior to and following portal vein embolization, which can be used in selected patients to increase the volume of the liver remnant prior to major hepatic resection [<a href="#rid84">84,85</a>]. (See <a class="local">'Portal vein embolization'</a> below.) </p><p>Increasingly, functional analyses in conjunction with CT volumetry are gaining acceptance when major resection is considered. As examples, combined volumetric-functional assessment using technetium hepatobiliary scintigraphy may be more accurate than volumetry alone in assessing risk for liver insufficiency/failure and mortality after major liver resection [<a href="#rid86">86,87</a>]. </p><p class="headingAnchor" id="H2252692213"><span class="h3">Other assessment tools</span><span class="headingEndMark"> — </span>Alternatively, many groups (especially in Asia) use clearance of <a class="drug drug_general" data-topicid="8982" href="/z/d/drug information/8982.html" rel="external">indocyanine green</a> at 15 minutes (ICG-15) as a defining criterion for selection of resection type [<a href="#rid88">88</a>]. Absence of portal hypertension as measured by the wedged hepatic venous pressure gradient may also be helpful [<a href="#rid6">6,89</a>]. However, these techniques have been widely adopted and are not yet considered the current standard of care in North America.</p><p class="headingAnchor" id="H1061867819"><span class="h2">Portal vein embolization</span><span class="headingEndMark"> — </span>Preoperative portal vein embolization (PVE) is a valuable adjunct to major liver resection, particularly for right-sided tumors [<a href="#rid84">84,90-93</a>]. PVE can initiate hypertrophy of the anticipated future liver remnant and allow a more extensive resection. (See  <a class="medical medical_review" href="/z/d/html/15094.html" rel="external">"Overview of hepatic resection", section on 'Preoperative PVE and other alternatives'</a> and  <a class="medical medical_review" href="/z/d/html/106477.html" rel="external">"Preoperative portal vein embolization", section on 'Introduction'</a>.)</p><p>Transarterial chemoembolization (TACE) has been proposed as a complementary procedure prior to PVE in patients with HCC [<a href="#rid94">94-103</a>]. TACE eliminates the arterial blood supply to the tumor and also embolizes potential arterioportal shunts that attenuate the effects of PVE in cirrhotic livers [<a href="#rid95">95,104</a>]. Complementary improvements in safety and disease-free and overall survival using combined TACE/PVE prior to resection have sparked further interest in this therapeutic sequence prior to right hepatectomy for HCC in cirrhosis [<a href="#rid94">94,95,104</a>]. </p><p>In a systematic review and meta-analysis of 40 studies of primary hepatobiliary cancers, PVE was typically performed in patients with HCC and presence of liver fibrosis or cirrhosis when either functional liver reserve (FLR) &lt;40 percent and liver function was good (ICG-15 &lt;10 percent) or when FLR &lt;50 percent and liver function was affected (ICG-15 10 to 20 percent) [<a href="#rid105">105</a>]. The median excision rate was 90 percent for HCCs. The combination of TACE and PVE increased hypertrophy rate and was associated with better disease-free and overall survival and should be considered in advanced HCC tumors with inadequate FLR. </p><p>PVE may have oncologic benefits beyond facilitating liver resection. Five-year disease-free survival and five-year overall survival were 17 to 49 percent and 12 to 53 percent in non-PVE patients, and 21 to 78 percent and 44 to 72 percent in PVE patients, respectively [<a href="#rid106">106</a>].</p><p>Liver venous deprivation performed at the time of PVE may enhance speed of hypertrophy of the future liver remnant, although the experience with this approach remains early [<a href="#rid107">107</a>].</p><p class="headingAnchor" id="H882401841"><span class="h1">HEPATIC RESECTION</span><span class="headingEndMark"> — </span>The type of hepatic resection depends upon the location of the lesion(s) and presence, severity of cirrhosis, and surgeon preference. </p><p class="headingAnchor" id="H1624891760"><span class="h2">Anatomic versus nonanatomic resection</span><span class="headingEndMark"> — </span>Until further data are available, most surgeons recommend anatomic resection in noncirrhotic patients when feasible and safe based on analysis of liver function. But data are not conclusive in showing an oncologic benefit of anatomic resection for HCC in the setting of cirrhosis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anatomic resection</strong> – Anatomic resection of the liver follows the planes of the liver segments as delineated by Couinaud  (<a class="graphic graphic_figure graphicRef81897" href="/z/d/graphic/81897.html" rel="external">figure 3</a>). It is accomplished by selective ligation of the inflow portal triad and ligation of dominant outflow hepatic veins to the segment(s) that will be resected [<a href="#rid108">108</a>]. If subsegmental resection is planned, intraoperative ultrasonography facilitates localization of the intrahepatic vessels [<a href="#rid109">109-111</a>]. Anatomic resection is largely used for resecting HCC in noncirrhotic patients, in whom up to two-thirds of functional parenchyma can be removed safely depending upon the age of the patient [<a href="#rid112">112</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonanatomic resection</strong> – For cirrhotic patients, the resection needs to remove the least amount of nonmalignant parenchyma possible to preserve postoperative liver function  (<a class="graphic graphic_picture graphicRef64800" href="/z/d/graphic/64800.html" rel="external">picture 1</a>). Because the capacity for liver regeneration is impaired in cirrhotics, resection is generally limited to &lt;25 percent of the functional parenchyma [<a href="#rid112">112</a>]. Thus, nonanatomic resection may be necessary to minimize the loss of functioning parenchyma in patients with cirrhosis [<a href="#rid113">113</a>]. (See <a class="local">'Portal vein embolization'</a> above and  <a class="medical medical_review" href="/z/d/html/88319.html" rel="external">"Open hepatic resection techniques", section on 'Specific resections'</a>.)</p><p></p><p>In theory, the systematic removal of the hepatic segment supplied by tumor-bearing portal tributaries (ie, the entire functional unit) through an anatomic resection could eradicate tumors and metastases more effectively. Indeed, a meta-analysis of 43 studies associated anatomic resection with a disease-free survival (DFS) benefit at one (hazard ratio [HR] 0.79, 95% CI 0.68-0.92), three (HR 0.87, 95% CI 0.78-0.95) and five years (HR 0.87, 95% CI 0.82-0.93), as well as a decreased risk of death at five years (HR: 0.88, 95% CI 0.79-0.97); there was no difference in perioperative morbidity or mortality rates [<a href="#rid114">114</a>]. However, other studies found no significant difference in outcomes between anatomic and nonanatomic resections [<a href="#rid115">115-117</a>]. The extreme heterogeneity of the patient populations and tumor biology no doubt contributed to the discrepancy. As such, the benefit of anatomic resection is unknown, and future randomized trials are needed to directly compare the two strategies. </p><p class="headingAnchor" id="H882402433"><span class="h2">Anterior versus conventional approach</span><span class="headingEndMark"> — </span>The absence of a downside and significant technical advantage provided by the anterior approach (particularly with the liver-hanging maneuver) have led to widespread use of this technique in both open and minimally invasive liver surgery.</p><p class="bulletIndent1"><span class="glyph">●</span>The conventional technique of hepatectomy fully mobilizes the portion of the liver to be resected before initiating parenchymal division. (See  <a class="medical medical_review" href="/z/d/html/88319.html" rel="external">"Open hepatic resection techniques", section on 'General techniques'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For HCC, some surgeons have advocated an anterior or "no touch" technique for the resection of HCC. The anterior approach technique involves initial vascular inflow control, completion of parenchymal transection, and complete venous outflow control before the hemiliver was mobilized [<a href="#rid118">118</a>]. The advocates for this technique hypothesize that separation of the hemiliver and tumor from the IVC before mobilization reduces the risk of vessel rupture and theoretically minimizes the potential for tumor cell dissemination. </p><p></p><p>A meta-analysis of three trials and 13 other studies found that for right hepatectomy, the anterior approach was associated with less intraoperative blood loss and transfusion, morbidity (odds ratio [OR] 0.77, 95% CI 0.62-0.95), recurrence rate (OR 0.62, 95% CI 0.47-0.83), overall survival (HR 0.71, 95% CI 0.50-1.00), and disease-free survival (HR 0.67, 95% CI 0.58-0.79) compared with conventional hepatectomy [<a href="#rid119">119</a>]. </p><p>Additionally, with the additional modification to the anterior approach technique, the liver can be lifted with a tape, providing a tremendous technical advantage when addressing large tumors [<a href="#rid120">120</a>], and many authors have found the technical advantage alone a reason to use the anterior approach (with hanging maneuver). Although originally described for right hepatectomy, variations of the hanging maneuver may be used for other types of resections, including left lateral sectionectomy and left hepatectomy.</p><p class="headingAnchor" id="H882402440"><span class="h2">Centrally located HCCs</span><span class="headingEndMark"> — </span>Surgical management of centrally located HCCs (ie, those in segments IV, V, and VIII) is more problematic than peripherally located tumors  (<a class="graphic graphic_figure graphicRef81897" href="/z/d/graphic/81897.html" rel="external">figure 3</a>). </p><p class="bulletIndent1"><span class="glyph">●</span>Extended right or left hemihepatectomy is indicated if potentially curative surgery can be undertaken safely. However, these resections can be associated with high morbidity and mortality rates due to insufficient residual functional liver parenchyma [<a href="#rid121">121-123</a>]. (See  <a class="medical medical_review" href="/z/d/html/88319.html" rel="external">"Open hepatic resection techniques", section on 'Right extended hemihepatectomy'</a> and  <a class="medical medical_review" href="/z/d/html/88319.html" rel="external">"Open hepatic resection techniques", section on 'Left extended hemihepatectomy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An alternative approach, mesohepatectomy (also called central hepatectomy), is used in which the central liver segments IV and/or V, and VIII (with or without segment I), are removed, leaving the lateral sectors intact [<a href="#rid124">124,125</a>].</p><p></p><p>Although randomized trials have not been conducted, the available data suggest that mesohepatectomy is a reasonable alternative to extended hepatic resection for centrally located tumors, giving comparable oncologic outcomes with less liver parenchymal loss [<a href="#rid126">126,127</a>]. </p><p>Central hepatectomy has the advantage of not requiring a preoperative portal vein embolization and increased chances of a repeat hepatectomy in case of recurrence [<a href="#rid128">128</a>]. However, in some centers, it is seldom used, partly because it is a complex and technically demanding procedure that requires two hepatic resection planes and potentially bilateral biliary reconstruction. This could result in a higher risk of bleeding and postoperative bile leak as well as long-term biliary stricture and biliary dysfunction [<a href="#rid129">129</a>]. </p><p class="headingAnchor" id="H11"><span class="h2">Minimally invasive hepatic resection</span><span class="headingEndMark"> — </span>The available data support the view that, in experienced hands, laparoscopic or robotic resection is feasible and safe, but it is also highly technically demanding and should be undertaken only in high-volume centers with a program of graduated procedural complexity. (See  <a class="medical medical_review" href="/z/d/html/109268.html" rel="external">"Minimally invasive liver resection (MILR)"</a>.)</p><p>The following represents the range of findings in patients undergoing minimally invasive liver resection for HCC, although none of the included studies were randomized trials [<a href="#rid130">130</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>In a 2018 systematic review of 17 studies published in the preceding 10 years, over 1500 patients underwent laparoscopic liver resection for HCC, most with good liver function and a single HCC; 33 to 100 percent had cirrhosis as determined by pathology. Overall perioperative mortality and morbidity ranged from 0 to 2.4 percent and 4.9 to 44 percent, respectively. The overall survival rates ranged from 73 to 100 percent at one year, 61 to 94 percent at two years, and 38 to 90 percent at three years. Compared with open surgery, laparoscopic resection was associated with shorter operative time, lower complication rate, reduced blood loss and transfusion requirement, and a shorter hospital stay [<a href="#rid131">131</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2019 systematic review and meta-analysis of 24 studies comparing laparoscopic with open liver resection for HCC associated laparoscopic surgery with favorable short-term outcomes and comparable long-term outcomes [<a href="#rid132">132</a>]. Both minor and major liver resections, and both noncirrhotic and noncirrhotic patients were included in the studies. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2014 systematic review and meta-analysis of four studies specifically compared laparoscopic with open liver resection of HCC in cirrhotic patients [<a href="#rid133">133</a>]. Laparoscopic surgery was associated with less blood loss, wider margin, fewer complications, and shorter hospital study than open resection. Long-term and oncologic outcomes were not reported. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2020 systematic review and meta-analysis of 14 studies comparing robotic with laparoscopic liver resection for HCC found comparable short-term outcomes between the two techniques [<a href="#rid134">134</a>]. Despite that the tumor sizes were significantly larger in the robotic surgery group, the margin status was comparable. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2021 systematic review and meta-analysis of 26 studies comparing robotic with laparoscopic liver resection also found comparable short-term outcomes between the two techniques [<a href="#rid135">135</a>]. Robotic surgery took longer operative time but incurred less blood loss.</p><p></p><p>One advantage of a minimally invasive approach may be simplification of subsequent liver transplantation, if ultimately needed, due to fewer abdominal adhesions after the initial resection of HCC [<a href="#rid136">136</a>]. A second advantage may be the avoidance of division of abdominal wall collaterals associated with some abdominal incisions.</p><p class="headingAnchor" id="H12"><span class="h1">POSTOPERATIVE MORBIDITY AND MORTALITY</span><span class="headingEndMark"> — </span>Postoperative morbidity and mortality is related to the extent of operative resection as well as the underlying liver condition (cirrhosis versus noncirrhosis) [<a href="#rid137">137-140</a>]. There is increasing evidence that the surgical morbidities may be reduced by using minimally invasive liver resection techniques. (See <a class="local">'Minimally invasive hepatic resection'</a> above.)</p><p class="headingAnchor" id="H3596500910"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>The 30-day perioperative mortality rate in modern series of HCC resection is very low and ranges from 0 to 2 percent [<a href="#rid59">59,141-144</a>]. Consensus is growing that 30-day operative mortality is an inadequate indicator of risk, particularly of postoperative hepatic insufficiency and failure. Using an approach similar to liver transplantation reporting, 90-day mortality rates appear to be a more valuable indicator of outcome of liver resection, especially in the cases of extended resection and resection in patients with diseased livers [<a href="#rid145">145,146</a>]. This relates to the late development of slowly progressive jaundice, ascites, and eventual death, which typically occurs outside the hospital and well after 30 postoperative days in patients with marginal or inadequate liver remnants. The reported 90-day mortality rate in contemporary series ranges from 1.9 to 4.5 percent for noncirrhotic or Child-Pugh class A patients [<a href="#rid147">147,148</a>], and from 1.7 to 22 percent for Child-Pugh class B patients [<a href="#rid149">149-151</a>]. </p><p>Most deaths are due to postoperative liver failure, and fewer than 10 percent are due to complications from bleeding. Mortality can be reduced by appropriate selection of patients with the inclusion of preoperative volumetry and portal vein embolization when appropriate, and meticulous surgical technique, including techniques to minimize blood loss and the need for transfusion.</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of cirrhosis is the most important predictor of postresection liver failure and death. Major resection in cirrhotic patients without careful selection and/or portal vein embolization (PVE) continues to be a major challenge. Series assessing major resection in patients with cirrhosis without PVE continue to report mortality rates up to 18 percent compared with &lt;3 percent for those undergoing PVE [<a href="#rid94">94</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two additional factors influence the development of postoperative liver failure in cirrhotic patients: intraoperative blood loss of &gt;1500 mL and postoperative infection of any type [<a href="#rid152">152</a>]. Massive intraoperative blood loss (defined as &gt;800 mL) has also been independently associated with early postoperative mortality [<a href="#rid153">153,154</a>]. Postoperative infective complications have also been independently associated with decreased overall and disease-free survival [<a href="#rid155">155</a>].</p><p></p><p class="headingAnchor" id="H366798048"><span class="h2">Morbidities</span><span class="headingEndMark"> — </span>About half of the patients develop a complication after liver resection for HCC, and 7 to 11 percent develop a major complication [<a href="#rid156">156-158</a>]. Major complications include ascites, hepatic insufficiency, biliary fistula, hepatic abscess, hemoperitoneum, and pleural effusion [<a href="#rid158">158</a>]. </p><p class="headingAnchor" id="H17690277"><span class="h1">POSTTREATMENT SURVEILLANCE AND LONG-TERM OUTCOMES</span><span class="headingEndMark"> — </span>Models are being developed to predict the risk of recurrence after liver resection for HCC<strong> </strong>[<a href="#rid159">159,160</a>]. The long-term outcomes, benefit of adjuvant therapy, and recommendations for posttreatment surveillance after potentially curative resection are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/17215.html" rel="external">"Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance"</a> and  <a class="medical medical_review" href="/z/d/html/2476.html" rel="external">"Staging and prognostic factors in hepatocellular carcinoma"</a>.)</p><p class="headingAnchor" id="H4168265002"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119333.html" rel="external">"Society guideline links: Hepatocellular carcinoma"</a>.) </p><p class="headingAnchor" id="H25896948"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/16838.html" rel="external">"Patient education: Liver cancer (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1061866831"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of hepatocellular carcinoma</strong> – Hepatocellular carcinoma (HCC) is a tumor with highly variable biology that often occurs in the setting of chronic liver disease and cirrhosis. The treatment algorithms for HCC vary widely by geography, but all require comprehensive multidisciplinary care. (See <a class="local">'Introduction'</a> above and <a class="local">'Treatment algorithms for HCC'</a> above and <a class="local">'Importance of comprehensive multidisciplinary care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preoperative assessment</strong> – The preoperative evaluation for resection of HCC focuses on the likelihood of disease being confined to the liver and whether the size and location of the tumor and the patient's underlying liver function will permit resection. (See <a class="local">'Preoperative assessment for resectability'</a> above and <a class="local">'Assessment of hepatic reserve'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Exclude extrahepatic or portal metastasis</strong> – Most consider stage IIIB, IVA, and IVB disease to be incurable by resection  (<a class="graphic graphic_table graphicRef110835" href="/z/d/graphic/110835.html" rel="external">table 1</a>). These stages are defined by invasion of a major portal or hepatic vein, direct invasion of organs other than the gallbladder, perforation of the visceral peritoneum (IIIB), and nodal (IVA) or distant metastases (IVB). (See <a class="local">'Exclude extrahepatic metastasis'</a> above and <a class="local">'Exclude portal lymph node metastasis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Delineate tumor extent</strong> – Anatomic delineation of tumor extent is best achieved with dynamic multiphase CT, in which the nonenhanced, hepatic arterial, and portal venous phases are assessed separately, or with MRI scanning. Tumor size, multiple tumors, or tumor rupture are not universally considered contraindications to resection. (See <a class="local">'Delineate tumor extent'</a> above and <a class="local">'Determine resectability based on tumor extent'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Assess hepatic reserve</strong> – The volume and function of residual liver remnant can be assessed by clinical scores, hepatic volumetry, or other functional studies (eg, ICG-15) prior to major resection to minimize posthepatectomy liver failure. (See <a class="local">'Assessment of hepatic reserve'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Portal vein embolization</strong> – Preoperative portal vein embolization (PVE) or liver hepatic deprivation can initiate hypertrophy of the anticipated future liver remnant to enable an extended resection that would otherwise leave a remnant liver insufficient to support life following partial hepatectomy. Transarterial chemoembolization (TACE) may be combined with PVE. (See <a class="local">'Portal vein embolization'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatic resection for HCC</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For noncirrhotic patients undergoing curative hepatectomy for HCC, we suggest anatomic resection (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, nonanatomic resection may be necessary to minimize the loss of functioning parenchyma in patients with cirrhosis. (See <a class="local">'Anatomic versus nonanatomic resection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The anterior approach with a liver-hanging maneuver is preferred to the conventional approach by many surgeons for resecting large tumors. (See <a class="local">'Anterior versus conventional approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Central hepatectomy may better preserve liver parenchyma in patients with HCC in central lobes of the liver but can be technically challenging compared with extended hepatectomy. (See <a class="local">'Centrally located HCCs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Minimally invasive liver resection for HCC in the hands of experienced surgeons is safe and may reduce surgical morbidities (See <a class="local">'Minimally invasive hepatic resection'</a> above and  <a class="medical medical_review" href="/z/d/html/109268.html" rel="external">"Minimally invasive liver resection (MILR)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – In contemporary series, surgical mortality after liver resection for HCC is very rare (0 to 2 percent at 30 days and 2 to 5 percent at 90 days). Most deaths are due to postoperative liver failure; 10 percent are from massive blood loss or infection. Major surgical morbidity rates are also low at 7 to 11 percent. (See <a class="local">'Postoperative morbidity and mortality'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28:751.</a></li><li><a class="nounderline abstract_t">Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022; 76:681.</a></li><li><a class="nounderline abstract_t">Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017; 11:317.</a></li><li><a class="nounderline abstract_t">Bruix J. Treatment of hepatocellular carcinoma. Hepatology 1997; 25:259.</a></li><li><a class="nounderline abstract_t">Vauthey JN, Klimstra D, Franceschi D, et al. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am J Surg 1995; 169:28.</a></li><li><a class="nounderline abstract_t">Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996; 111:1018.</a></li><li><a class="nounderline abstract_t">Pawlik TM, Poon RT, Abdalla EK, et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005; 140:450.</a></li><li><a class="nounderline abstract_t">Roayaie S, Jibara G, Taouli B, Schwartz M. Resection of hepatocellular carcinoma with macroscopic vascular invasion. Ann Surg Oncol 2013; 20:3754.</a></li><li><a class="nounderline abstract_t">Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999; 229:790.</a></li><li><a class="nounderline abstract_t">Minagawa M, Ikai I, Matsuyama Y, et al. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg 2007; 245:909.</a></li><li><a class="nounderline abstract_t">Makuuchi M, Sano K. The surgical approach to HCC: our progress and results in Japan. Liver Transpl 2004; 10:S46.</a></li><li><a class="nounderline abstract_t">Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023; 78:1966.</a></li><li><a class="nounderline abstract_t">Saitta C, Pollicino T, Raimondo G. Obesity and liver cancer. Ann Hepatol 2019; 18:810.</a></li><li><a class="nounderline abstract_t">Berkan-Kawińska A, Piekarska A. Hepatocellular carcinoma in non-alcohol fatty liver disease - changing trends and specific challenges. Curr Med Res Opin 2020; 36:235.</a></li><li><a class="nounderline abstract_t">Okuno M, Newhook TE, Joechle K, et al. Characteristics of atypical large well-differentiated hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma? HPB (Oxford) 2020; 22:545.</a></li><li><a class="nounderline abstract_t">Koh YX, Tan HJ, Liew YX, et al. Liver Resection for Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma. J Am Coll Surg 2019; 229:467.</a></li><li><a class="nounderline abstract_t">Serper M, Taddei TH, Mehta R, et al. Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality. Gastroenterology 2017; 152:1954.</a></li><li><a class="nounderline abstract_t">Lo CM, Lai EC, Liu CL, et al. Laparoscopy and laparoscopic ultrasonography avoid exploratory laparotomy in patients with hepatocellular carcinoma. Ann Surg 1998; 227:527.</a></li><li><a class="nounderline abstract_t">Wu W, He X, Andayani D, et al. Pattern of distant extrahepatic metastases in primary liver cancer: a SEER based study. J Cancer 2017; 8:2312.</a></li><li class="breakAll">National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary Cancers. Version 1.2020 - March 23, 2020. Available at: https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf (Accessed on May 05, 2020).</li><li><a class="nounderline abstract_t">Lai EC, Tang CN, Ha JP, et al. The evolving influence of laparoscopy and laparoscopic ultrasonography on patients with hepatocellular carcinoma. Am J Surg 2008; 196:736.</a></li><li><a class="nounderline abstract_t">Rethy A, Langø T, Mårvik R. Laparoscopic ultrasound for hepatocellular carcinoma and colorectal liver metastasis: an overview. Surg Laparosc Endosc Percutan Tech 2013; 23:135.</a></li><li><a class="nounderline abstract_t">Kose E, Kahramangil B, Purysko AS, et al. The utility of laparoscopic ultrasound during minimally invasive liver procedures in patients with malignant liver tumors who have undergone preoperative magnetic resonance imaging. Surg Endosc 2022; 36:4939.</a></li><li><a class="nounderline abstract_t">Bartoș A, Iancu I, Ciobanu L, et al. Intraoperative ultrasound in liver and pancreatic surgery. Med Ultrason 2021; 23:319.</a></li><li><a class="nounderline abstract_t">Kobayashi S, Takahashi S, Kato Y, et al. Surgical treatment of lymph node metastases from hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2011; 18:559.</a></li><li><a class="nounderline abstract_t">Xiaohong S, Huikai L, Feng W, et al. Clinical significance of lymph node metastasis in patients undergoing partial hepatectomy for hepatocellular carcinoma. World J Surg 2010; 34:1028.</a></li><li><a class="nounderline abstract_t">Hashimoto M, Matsuda M, Watanabe G. Metachronous resection of metastatic lymph nodes in patients with hepatocellular carcinoma. Hepatogastroenterology 2009; 56:788.</a></li><li><a class="nounderline abstract_t">Grobmyer SR, Wang L, Gonen M, et al. Perihepatic lymph node assessment in patients undergoing partial hepatectomy for malignancy. Ann Surg 2006; 244:260.</a></li><li><a class="nounderline abstract_t">Ercolani G, Grazi GL, Ravaioli M, et al. The role of lymphadenectomy for liver tumors: further considerations on the appropriateness of treatment strategy. Ann Surg 2004; 239:202.</a></li><li><a class="nounderline abstract_t">Sun HC, Zhuang PY, Qin LX, et al. Incidence and prognostic values of lymph node metastasis in operable hepatocellular carcinoma and evaluation of routine complete lymphadenectomy. J Surg Oncol 2007; 96:37.</a></li><li><a class="nounderline abstract_t">Dodd GD 3rd, Baron RL, Oliver JH 3rd, et al. Enlarged abdominal lymph nodes in end-stage cirrhosis: CT-histopathologic correlation in 507 patients. Radiology 1997; 203:127.</a></li><li><a class="nounderline abstract_t">Kimura H, Matsubayashi H, Fukutomi A, et al. Lymph node metastasis diagnosed by EUS-FNA in four cases with hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2011; 35:237.</a></li><li><a class="nounderline abstract_t">Murakami T, Kim T, Kawata S, et al. Evaluation of optimal timing of arterial phase imaging for the detection of hypervascular hepatocellular carcinoma by using triple arterial phase imaging with multidetector-row helical computed tomography. Invest Radiol 2003; 38:497.</a></li><li><a class="nounderline abstract_t">Iannaccone R, Laghi A, Catalano C, et al. Hepatocellular carcinoma: role of unenhanced and delayed phase multi-detector row helical CT in patients with cirrhosis. Radiology 2005; 234:460.</a></li><li><a class="nounderline abstract_t">Laghi A, Iannaccone R, Rossi P, et al. Hepatocellular carcinoma: detection with triple-phase multi-detector row helical CT in patients with chronic hepatitis. Radiology 2003; 226:543.</a></li><li><a class="nounderline abstract_t">Rode A, Bancel B, Douek P, et al. Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr 2001; 25:327.</a></li><li><a class="nounderline abstract_t">Burrel M, Llovet JM, Ayuso C, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38:1034.</a></li><li><a class="nounderline abstract_t">Kim YK, Kim CS, Chung GH, et al. Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma. AJR Am J Roentgenol 2006; 186:149.</a></li><li><a class="nounderline abstract_t">Kim SS, Kim SH, Song KD, et al. Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (&lt;3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study. J Magn Reson Imaging 2020; 51:70.</a></li><li><a class="nounderline abstract_t">Rimola J, Forner A, Sapena V, et al. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma. Eur Radiol 2020; 30:186.</a></li><li><a class="nounderline abstract_t">Kierans AS, Makkar J, Guniganti P, et al. Validation of Liver Imaging Reporting and Data System 2017 (LI-RADS) Criteria for Imaging Diagnosis of Hepatocellular Carcinoma. J Magn Reson Imaging 2019; 49:e205.</a></li><li><a class="nounderline abstract_t">Andreou A, Vauthey JN, Cherqui D, et al. Improved long-term survival after major resection for hepatocellular carcinoma: a multicenter analysis based on a new definition of major hepatectomy. J Gastrointest Surg 2013; 17:66.</a></li><li><a class="nounderline abstract_t">Shrager B, Jibara GA, Tabrizian P, et al. Resection of large hepatocellular carcinoma (≥10 cm): a unique western perspective. J Surg Oncol 2013; 107:111.</a></li><li><a class="nounderline abstract_t">Allemann P, Demartines N, Bouzourene H, et al. Long-term outcome after liver resection for hepatocellular carcinoma larger than 10 cm. World J Surg 2013; 37:452.</a></li><li><a class="nounderline abstract_t">Yang LY, Fang F, Ou DP, et al. Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg 2009; 249:118.</a></li><li><a class="nounderline abstract_t">Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002; 20:1527.</a></li><li><a class="nounderline abstract_t">Nagasue N, Kohno H, Chang YC, et al. Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg 1993; 217:375.</a></li><li><a class="nounderline abstract_t">Pandey D, Lee KH, Wai CT, et al. Long term outcome and prognostic factors for large hepatocellular carcinoma (10 cm or more) after surgical resection. Ann Surg Oncol 2007; 14:2817.</a></li><li><a class="nounderline abstract_t">Hanazaki K, Kajikawa S, Shimozawa N, et al. Hepatic resection for large hepatocellular carcinoma. Am J Surg 2001; 181:347.</a></li><li><a class="nounderline abstract_t">Hanazaki K, Kajikawa S, Shimozawa N, et al. Hepatic resection for hepatocellular carcinoma in diameter of &gt; or = 10 cm. Hepatogastroenterology 2002; 49:518.</a></li><li><a class="nounderline abstract_t">Lee NH, Chau GY, Lui WY, et al. Surgical treatment and outcome in patients with a hepatocellular carcinoma greater than 10 cm in diameter. Br J Surg 1998; 85:1654.</a></li><li><a class="nounderline abstract_t">Yeh CN, Lee WC, Chen MF. Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10 cm: two decades of experience at Chang Gung memorial hospital. Ann Surg Oncol 2003; 10:1070.</a></li><li><a class="nounderline abstract_t">Liau KH, Ruo L, Shia J, et al. Outcome of partial hepatectomy for large (&gt; 10 cm) hepatocellular carcinoma. Cancer 2005; 104:1948.</a></li><li><a class="nounderline abstract_t">Ariizumi S, Kotera Y, Takahashi Y, et al. Impact of hepatectomy for huge solitary hepatocellular carcinoma. J Surg Oncol 2013; 107:408.</a></li><li><a class="nounderline abstract_t">Shindoh J, Andreou A, Aloia TA, et al. Microvascular invasion does not predict long-term survival in hepatocellular carcinoma up to 2 cm: reappraisal of the staging system for solitary tumors. Ann Surg Oncol 2013; 20:1223.</a></li><li><a class="nounderline abstract_t">Lee S, Kang TW, Song KD, et al. Effect of Microvascular Invasion Risk on Early Recurrence of Hepatocellular Carcinoma After Surgery and Radiofrequency Ablation. Ann Surg 2021; 273:564.</a></li><li><a class="nounderline abstract_t">Chang YJ, Chung KP, Chang YJ, Chen LJ. Long-term survival of patients undergoing liver resection for very large hepatocellular carcinomas. Br J Surg 2016; 103:1513.</a></li><li><a class="nounderline abstract_t">Lee AJ, Wu AG, Yew KC, Shelat VG. Does size matter for resection of giant versus non-giant hepatocellular carcinoma? A meta-analysis. World J Gastrointest Surg 2023; 15:273.</a></li><li><a class="nounderline abstract_t">Li ZL, Yu JJ, Guo JW, et al. Liver resection is justified for multinodular hepatocellular carcinoma in selected patients with cirrhosis: A multicenter analysis of 1,066 patients. Eur J Surg Oncol 2019; 45:800.</a></li><li><a class="nounderline abstract_t">Glantzounis GK, Paliouras A, Stylianidi MC, et al. The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic review. Eur J Surg Oncol 2018; 44:195.</a></li><li><a class="nounderline abstract_t">Sahu SK, Chawla YK, Dhiman RK, et al. Rupture of Hepatocellular Carcinoma: A Review of Literature. J Clin Exp Hepatol 2019; 9:245.</a></li><li><a class="nounderline abstract_t">Hsueh KC, Fan HL, Chen TW, et al. Management of spontaneously ruptured hepatocellular carcinoma and hemoperitoneum manifested as acute abdomen in the emergency room. World J Surg 2012; 36:2670.</a></li><li><a class="nounderline abstract_t">Mise Y, Imamura H, Hashimoto T, et al. Cohort study of the survival benefit of resection for recurrent hepatic and/or pulmonary metastases after primary hepatectomy for colorectal metastases. Ann Surg 2010; 251:902.</a></li><li><a class="nounderline abstract_t">Lang BH, Poon RT, Fan ST, Wong J. Influence of laparoscopy on postoperative recurrence and survival in patients with ruptured hepatocellular carcinoma undergoing hepatic resection. Br J Surg 2004; 91:444.</a></li><li><a class="nounderline abstract_t">Liu CL, Fan ST, Lo CM, et al. Management of spontaneous rupture of hepatocellular carcinoma: single-center experience. J Clin Oncol 2001; 19:3725.</a></li><li><a class="nounderline abstract_t">Marini P, Vilgrain V, Belghiti J. Management of spontaneous rupture of liver tumours. Dig Surg 2002; 19:109.</a></li><li><a class="nounderline abstract_t">Takebayashi T, Kondo S, Ambo Y, et al. Staged hepatectomy following arterial embolization for ruptured hepatocellular carcinoma. Hepatogastroenterology 2002; 49:1074.</a></li><li><a class="nounderline abstract_t">Yeh CN, Lee WC, Jeng LB, et al. Spontaneous tumour rupture and prognosis in patients with hepatocellular carcinoma. Br J Surg 2002; 89:1125.</a></li><li><a class="nounderline abstract_t">Huang JF, Wu SM, Wu TH, et al. Liver resection for complicated hepatocellular carcinoma: challenges but opportunity for long-term survivals. J Surg Oncol 2012; 106:959.</a></li><li><a class="nounderline abstract_t">Aoki T, Kokudo N, Matsuyama Y, et al. Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide survey. Ann Surg 2014; 259:532.</a></li><li><a class="nounderline abstract_t">Zhang SY, Guo DZ, Zhang X, et al. Prognosis of spontaneously ruptured hepatocellular carcinoma: a propensity score matching study. J Cancer Res Clin Oncol 2023; 149:8889.</a></li><li><a class="nounderline abstract_t">Colleoni M, Audisio RA, De Braud F, et al. Practical considerations in the treatment of hepatocellular carcinoma. Drugs 1998; 55:367.</a></li><li><a class="nounderline abstract_t">Azoulay D, Ramos E, Casellas-Robert M, et al. Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension. JHEP Rep 2021; 3:100190.</a></li><li><a class="nounderline abstract_t">Imamura H, Seyama Y, Kokudo N, et al. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg 2003; 138:1198.</a></li><li><a class="nounderline abstract_t">Kamiyama T, Nakanishi K, Yokoo H, et al. Perioperative management of hepatic resection toward zero mortality and morbidity: analysis of 793 consecutive cases in a single institution. J Am Coll Surg 2010; 211:443.</a></li><li><a class="nounderline abstract_t">Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002; 236:397.</a></li><li><a class="nounderline abstract_t">She WH, Chok KSh. Strategies to increase the resectability of hepatocellular carcinoma. World J Hepatol 2015; 7:2147.</a></li><li><a class="nounderline abstract_t">Sotiropoulos GC, Lang H, Frilling A, et al. Resectability of hepatocellular carcinoma: evaluation of 333 consecutive cases at a single hepatobiliary specialty center and systematic review of the literature. Hepatogastroenterology 2006; 53:322.</a></li><li><a class="nounderline abstract_t">Makuuchi M, Kosuge T, Takayama T, et al. Surgery for small liver cancers. Semin Surg Oncol 1993; 9:298.</a></li><li><a class="nounderline abstract_t">Imamura H, Sano K, Sugawara Y, et al. Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. J Hepatobiliary Pancreat Surg 2005; 12:16.</a></li><li><a class="nounderline abstract_t">Demirtas CO, D'Alessio A, Rimassa L, et al. ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep 2021; 3:100347.</a></li><li><a class="nounderline abstract_t">Zhang ZQ, Xiong L, Zhou JJ, et al. Ability of the ALBI grade to predict posthepatectomy liver failure and long-term survival after liver resection for different BCLC stages of HCC. World J Surg Oncol 2018; 16:208.</a></li><li><a class="nounderline abstract_t">Tsai YC, Sou FM, Liu YW, et al. Preoperative ALBI grade predicts the outcomes in non-B non-C HCC patients undergoing primary curative resection. BMC Gastroenterol 2021; 21:386.</a></li><li><a class="nounderline abstract_t">Abdalla EK, Hicks ME, Vauthey JN. Portal vein embolization: rationale, technique and future prospects. Br J Surg 2001; 88:165.</a></li><li><a class="nounderline abstract_t">Farges O, Belghiti J, Kianmanesh R, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003; 237:208.</a></li><li><a class="nounderline abstract_t">Cieslak KP, Bennink RJ, de Graaf W, et al. Measurement of liver function using hepatobiliary scintigraphy improves risk assessment in patients undergoing major liver resection. HPB (Oxford) 2016; 18:773.</a></li><li><a class="nounderline abstract_t">de Graaf W, van Lienden KP, Dinant S, et al. Assessment of future remnant liver function using hepatobiliary scintigraphy in patients undergoing major liver resection. J Gastrointest Surg 2010; 14:369.</a></li><li class="breakAll">Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer (in Japanese), 4th ed, Kanehara and Co, Tokyo.</li><li><a class="nounderline abstract_t">Stremitzer S, Tamandl D, Kaczirek K, et al. Value of hepatic venous pressure gradient measurement before liver resection for hepatocellular carcinoma. Br J Surg 2011; 98:1752.</a></li><li><a class="nounderline abstract_t">Imamura H, Shimada R, Kubota M, et al. Preoperative portal vein embolization: an audit of 84 patients. Hepatology 1999; 29:1099.</a></li><li><a class="nounderline abstract_t">Abulkhir A, Limongelli P, Healey AJ, et al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg 2008; 247:49.</a></li><li><a class="nounderline abstract_t">Yoo H, Kim JH, Ko GY, et al. Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization only before major hepatectomy for patients with hepatocellular carcinoma. Ann Surg Oncol 2011; 18:1251.</a></li><li><a class="nounderline abstract_t">Leung U, Simpson AL, Araujo RL, et al. Remnant growth rate after portal vein embolization is a good early predictor of post-hepatectomy liver failure. J Am Coll Surg 2014; 219:620.</a></li><li><a class="nounderline abstract_t">Palavecino M, Chun YS, Madoff DC, et al. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Surgery 2009; 145:399.</a></li><li><a class="nounderline abstract_t">Ogata S, Belghiti J, Farges O, et al. Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma. Br J Surg 2006; 93:1091.</a></li><li><a class="nounderline abstract_t">Wu CC, Ho YZ, Ho WL, et al. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 1995; 82:122.</a></li><li><a class="nounderline abstract_t">Sasaki A, Iwashita Y, Shibata K, et al. Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma. Eur J Surg Oncol 2006; 32:773.</a></li><li><a class="nounderline abstract_t">Meric F, Patt YZ, Curley SA, et al. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol 2000; 7:490.</a></li><li><a class="nounderline abstract_t">Zhong C, Guo RP, Li JQ, et al. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol 2009; 135:1437.</a></li><li><a class="nounderline abstract_t">Harada T, Matsuo K, Inoue T, et al. Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma? Ann Surg 1996; 224:4.</a></li><li><a class="nounderline abstract_t">Uchida M, Kohno H, Kubota H, et al. Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma. World J Surg 1996; 20:326.</a></li><li><a class="nounderline abstract_t">Fan J, Tang ZY, Yu YQ, et al. Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma. Dig Surg 1998; 15:674.</a></li><li><a class="nounderline abstract_t">Lee KT, Lu YW, Wang SN, et al. The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes. J Surg Oncol 2009; 99:343.</a></li><li><a class="nounderline abstract_t">Aoki T, Imamura H, Hasegawa K, et al. Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg 2004; 139:766.</a></li><li><a class="nounderline abstract_t">Glantzounis GK, Tokidis E, Basourakos SP, et al. The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review. Eur J Surg Oncol 2017; 43:32.</a></li><li><a class="nounderline abstract_t">Beppu T, Yamamura K, Okabe H, et al. Oncological benefits of portal vein embolization for patients with hepatocellular carcinoma. Ann Gastroenterol Surg 2021; 5:287.</a></li><li><a class="nounderline abstract_t">Ayabe RI, Vauthey JN, Newhook TE. Optimizing the future liver remnant: Portal vein embolization, hepatic venous deprivation, and associating liver partition and portal vein ligation for staged hepatectomy. Surgery 2023; 174:116.</a></li><li><a class="nounderline abstract_t">Gonzalez RJ, Barnett CC Jr. A technique for safely teaching major hepatectomy to surgical residents. Am J Surg 2008; 195:521.</a></li><li><a class="nounderline abstract_t">Torzilli G, Procopio F, Donadon M, et al. Anatomical right posterior sectionectomy: a further expansion of the ultrasound-guided compression technique. Updates Surg 2011; 63:91.</a></li><li><a class="nounderline abstract_t">Takayama T, Makuuchi M, Watanabe K, et al. A new method for mapping hepatic subsegment: counterstaining identification technique. Surgery 1991; 109:226.</a></li><li><a class="nounderline abstract_t">Donadon M, Torzilli G. Intraoperative ultrasound in patients with hepatocellular carcinoma: from daily practice to future trends. Liver Cancer 2013; 2:16.</a></li><li><a class="nounderline abstract_t">Cassese G, Han HS, Al Farai A, et al. Future remnant liver optimization: preoperative assessment, volume augmentation procedures and management of PVE failure. Minerva Surg 2022; 77:368.</a></li><li><a class="nounderline abstract_t">Tomimaru Y, Eguchi H, Marubashi S, et al. Equivalent outcomes after anatomical and non-anatomical resection of small hepatocellular carcinoma in patients with preserved liver function. Dig Dis Sci 2012; 57:1942.</a></li><li><a class="nounderline abstract_t">Moris D, Tsilimigras DI, Kostakis ID, et al. Anatomic versus non-anatomic resection for hepatocellular carcinoma: A systematic review and meta-analysis. Eur J Surg Oncol 2018; 44:927.</a></li><li><a class="nounderline abstract_t">Marubashi S, Gotoh K, Akita H, et al. Anatomical versus non-anatomical resection for hepatocellular carcinoma. Br J Surg 2015; 102:776.</a></li><li><a class="nounderline abstract_t">Famularo S, Ceresoli M, Giani A, et al. Is It Just a Matter of Surgical Extension to Achieve the Cure of Hepatocarcinoma? A Meta-Analysis of Propensity-Matched and Randomized Studies for Anatomic Versus Parenchyma-Sparing Liver Resection. J Gastrointest Surg 2021; 25:94.</a></li><li><a class="nounderline abstract_t">Famularo S, Di Sandro S, Giani A, et al. Long-term oncologic results of anatomic vs. parenchyma-sparing resection for hepatocellular carcinoma. A propensity score-matching analysis. Eur J Surg Oncol 2018; 44:1580.</a></li><li><a class="nounderline abstract_t">Liu CL, Fan ST, Cheung ST, et al. Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study. Ann Surg 2006; 244:194.</a></li><li><a class="nounderline abstract_t">Tang JX, Li JJ, Weng RH, et al. Anterior vs conventional approach right hepatic resection for large hepatocellular carcinoma: A systematic review and meta-analysis. World J Gastroenterol 2017; 23:7917.</a></li><li><a class="nounderline abstract_t">Nanashima A, Hiyoshi M, Imamura N, et al. Liver hanging maneuver is suitable in major hepatectomy for liver malignancies over 5 cm. Turk J Surg 2022; 38:215.</a></li><li><a class="nounderline abstract_t">Rui JA, Wang SB, Chen SG, Zhou L. Right trisectionectomy for primary liver cancer. World J Gastroenterol 2003; 9:706.</a></li><li><a class="nounderline abstract_t">Wei AC, Tung-Ping Poon R, Fan ST, Wong J. Risk factors for perioperative morbidity and mortality after extended hepatectomy for hepatocellular carcinoma. Br J Surg 2003; 90:33.</a></li><li><a class="nounderline abstract_t">Melendez J, Ferri E, Zwillman M, et al. Extended hepatic resection: a 6-year retrospective study of risk factors for perioperative mortality. J Am Coll Surg 2001; 192:47.</a></li><li><a class="nounderline abstract_t">Mehrabi A, Mood ZA, Roshanaei N, et al. Mesohepatectomy as an option for the treatment of central liver tumors. J Am Coll Surg 2008; 207:499.</a></li><li><a class="nounderline abstract_t">Scudamore CH, Buczkowski AK, Shayan H, et al. Mesohepatectomy. Am J Surg 2000; 179:356.</a></li><li><a class="nounderline abstract_t">de'Angelis N, Pascal G, Salloum C, et al. Central Hepatectomy versus Extended Hepatectomy for Malignant Tumors: A Propensity Score Analysis of Postoperative Complications. World J Surg 2016; 40:2745.</a></li><li><a class="nounderline abstract_t">Gadallah EA, Elkomos BE, Khalil A, et al. Central hepatectomy versus major hepatectomy for patients with centrally located hepatocellular carcinoma: a systematic review and meta-analysis. BMC Surg 2023; 23:2.</a></li><li><a class="nounderline abstract_t">Orimo T, Kamiyama T, Kakisaka T, et al. Central Hepatectomy Versus Major Hepatectomy for Centrally Located Hepatocellular Carcinoma: A Propensity Score Matching Study. Ann Surg Oncol 2021; 28:6769.</a></li><li><a class="nounderline abstract_t">Nanashima A, Eguchi S, Hisaka T, et al. Risk Factors of Complications from Central Bisectionectomy (H458) for Hepatocellular Carcinoma: A Multi-Institutional Single-Arm Analysis. Cancers (Basel) 2023; 15.</a></li><li><a class="nounderline abstract_t">Ng KKC, Chong CCN, Lee KF, et al. Asia-Pacific multicentre randomized trial of laparoscopic versus open major hepatectomy for hepatocellular carcinoma (AP-LAPO trial). BJS Open 2023; 7.</a></li><li><a class="nounderline abstract_t">Di Sandro S, Danieli M, Ferla F, et al. The current role of laparoscopic resection for HCC: a systematic review of past ten years. Transl Gastroenterol Hepatol 2018; 3:68.</a></li><li><a class="nounderline abstract_t">Ciria R, Gomez-Luque I, Ocaña S, et al. A Systematic Review and Meta-Analysis Comparing the Short- and Long-Term Outcomes for Laparoscopic and Open Liver Resections for Hepatocellular Carcinoma: Updated Results from the European Guidelines Meeting on Laparoscopic Liver Surgery, Southampton, UK, 2017. Ann Surg Oncol 2019; 26:252.</a></li><li><a class="nounderline abstract_t">Twaij A, Pucher PH, Sodergren MH, et al. Laparoscopic vs open approach to resection of hepatocellular carcinoma in patients with known cirrhosis: systematic review and meta-analysis. World J Gastroenterol 2014; 20:8274.</a></li><li><a class="nounderline abstract_t">Rahimli M, Perrakis A, Andric M, et al. Does Robotic Liver Surgery Enhance R0 Results in Liver Malignancies during Minimally Invasive Liver Surgery?-A Systematic Review and Meta-Analysis. Cancers (Basel) 2022; 14.</a></li><li><a class="nounderline abstract_t">Kamarajah SK, Bundred J, Manas D, et al. Robotic versus conventional laparoscopic liver resections: A systematic review and meta-analysis. Scand J Surg 2021; 110:290.</a></li><li><a class="nounderline abstract_t">Belghiti J, Cortes A, Abdalla EK, et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 2003; 238:885.</a></li><li><a class="nounderline abstract_t">Liu L, Wang Z, Jiang S, et al. Perioperative allogenenic blood transfusion is associated with worse clinical outcomes for hepatocellular carcinoma: a meta-analysis. PLoS One 2013; 8:e64261.</a></li><li><a class="nounderline abstract_t">Nanashima A, Yamaguchi H, Shibasaki S, et al. Comparative analysis of postoperative morbidity according to type and extent of hepatectomy. Hepatogastroenterology 2005; 52:844.</a></li><li><a class="nounderline abstract_t">Nathan H, Schulick RD, Choti MA, Pawlik TM. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg 2009; 249:799.</a></li><li><a class="nounderline abstract_t">Wayne JD, Lauwers GY, Ikai I, et al. Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg 2002; 235:722.</a></li><li><a class="nounderline abstract_t">Xourafas D, Pawlik TM, Cloyd JM. Early Morbidity and Mortality after Minimally Invasive Liver Resection for Hepatocellular Carcinoma: a Propensity-Score Matched Comparison with Open Resection. J Gastrointest Surg 2019; 23:1435.</a></li><li><a class="nounderline abstract_t">Li J, Huang L, Yan J, et al. Liver resection for hepatocellular carcinoma: personal experiences in a series of 1330 consecutive cases in China. ANZ J Surg 2018; 88:E713.</a></li><li><a class="nounderline abstract_t">Torzilli G, Makuuchi M, Inoue K, et al. No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach. Arch Surg 1999; 134:984.</a></li><li><a class="nounderline abstract_t">Lee EC, Kim SH, Park H, et al. Survival analysis after liver resection for hepatocellular carcinoma: A consecutive cohort of 1002 patients. J Gastroenterol Hepatol 2017; 32:1055.</a></li><li><a class="nounderline abstract_t">Mullen JT, Ribero D, Reddy SK, et al. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg 2007; 204:854.</a></li><li><a class="nounderline abstract_t">Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24:2065.</a></li><li><a class="nounderline abstract_t">Herman P, Fonseca GM, Coelho FF, et al. Two decades of liver resection with a multidisciplinary approach in a single institution: What has changed? Analysis of 1409 cases. Clinics (Sao Paulo) 2022; 77:100088.</a></li><li><a class="nounderline abstract_t">Thelen A, Benckert C, Tautenhahn HM, et al. Liver resection for hepatocellular carcinoma in patients without cirrhosis. Br J Surg 2013; 100:130.</a></li><li><a class="nounderline abstract_t">Shirata C, Hasegawa K, Kokudo T, et al. Liver Resection for Hepatocellular Carcinoma in Patients with Renal Dysfunction. World J Surg 2018; 42:4054.</a></li><li><a class="nounderline abstract_t">Troisi RI, Berardi G, Morise Z, et al. Laparoscopic and open liver resection for hepatocellular carcinoma with Child-Pugh B cirrhosis: multicentre propensity score-matched study. Br J Surg 2021; 108:196.</a></li><li><a class="nounderline abstract_t">Tanaka S, Noda T, Komeda K, et al. Surgical Outcomes for Hepatocellular Carcinoma in Patients with Child-Pugh Class B: a Retrospective Multicenter Study. J Gastrointest Surg 2023; 27:283.</a></li><li><a class="nounderline abstract_t">Takenaka K, Kanematsu T, Fukuzawa K, Sugimachi K. Can hepatic failure after surgery for hepatocellular carcinoma in cirrhotic patients be prevented? World J Surg 1990; 14:123.</a></li><li><a class="nounderline abstract_t">Imai D, Maeda T, Wang H, et al. Risk Factors for and Outcomes of Intraoperative Blood Loss in Liver Resection for Hepatocellular Tumors. Am Surg 2021; 87:376.</a></li><li><a class="nounderline abstract_t">Lee CW, Tsai HI, Sung CM, et al. Risk factors for early mortality after hepatectomy for hepatocellular carcinoma. Medicine (Baltimore) 2016; 95:e5028.</a></li><li><a class="nounderline abstract_t">Yang T, Liu K, Liu CF, et al. Impact of postoperative infective complications on long-term survival after liver resection for hepatocellular carcinoma. Br J Surg 2019; 106:1228.</a></li><li><a class="nounderline abstract_t">Benzoni E, Molaro R, Cedolini C, et al. Liver resection for HCC: analysis of causes and risk factors linked to postoperative complications. Hepatogastroenterology 2007; 54:186.</a></li><li><a class="nounderline abstract_t">Lee B, Cho JY, Han HS, et al. A scoring system to predict the risk of major complications after laparoscopic liver resection in elderly patients with hepatocellular carcinoma. Surg Endosc 2022; 36:7756.</a></li><li><a class="nounderline abstract_t">Wu HL, Liu HY, Liu WC, et al. A predictive model incorporating inflammation markers for high-grade surgical complications following liver resection for hepatocellular carcinoma. J Chin Med Assoc 2022; 85:845.</a></li><li><a class="nounderline abstract_t">Li Y, Ruan DY, Yi HM, et al. A three-factor preoperative scoring model predicts risk of recurrence after liver resection or transplantation in hepatocellular carcinoma patients with preserved liver function. Hepatobiliary Pancreat Dis Int 2015; 14:477.</a></li><li><a class="nounderline abstract_t">Dekervel J, Popovic D, van Malenstein H, et al. A Global Risk Score (GRS) to Simultaneously Predict Early and Late Tumor Recurrence Risk after Resection of Hepatocellular Carcinoma. Transl Oncol 2016; 9:139.</a></li></ol></div><div id="topicVersionRevision">Topic 2488 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9731568" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34801630" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28620797" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9021931" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Treatment of hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7817995" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8831597" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15897440" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23884750" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Resection of hepatocellular carcinoma with macroscopic vascular invasion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10363892" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : An analysis of 412 cases of hepatocellular carcinoma at a Western center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17522517" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14762839" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The surgical approach to HCC: our progress and results in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37363821" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A multisociety Delphi consensus statement on new fatty liver disease nomenclature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31543467" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Obesity and liver cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31631714" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hepatocellular carcinoma in non-alcohol fatty liver disease - changing trends and specific challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31533893" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Characteristics of atypical large well-differentiated hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31398386" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Liver Resection for Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28283421" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9563541" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Laparoscopy and laparoscopic ultrasonography avoid exploratory laparotomy in patients with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28819435" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pattern of distant extrahepatic metastases in primary liver cancer: a SEER based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28819435" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pattern of distant extrahepatic metastases in primary liver cancer: a SEER based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18558389" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The evolving influence of laparoscopy and laparoscopic ultrasonography on patients with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23579506" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Laparoscopic ultrasound for hepatocellular carcinoma and colorectal liver metastasis: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34734301" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The utility of laparoscopic ultrasound during minimally invasive liver procedures in patients with malignant liver tumors who have undergone preoperative magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33626120" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Intraoperative ultrasound in liver and pancreatic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21331804" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Surgical treatment of lymph node metastases from hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20174806" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinical significance of lymph node metastasis in patients undergoing partial hepatectomy for hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19621703" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Metachronous resection of metastatic lymph nodes in patients with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16858189" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Perihepatic lymph node assessment in patients undergoing partial hepatectomy for malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14745328" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The role of lymphadenectomy for liver tumors: further considerations on the appropriateness of treatment strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17345597" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Incidence and prognostic values of lymph node metastasis in operable hepatocellular carcinoma and evaluation of routine complete lymphadenectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9122379" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Enlarged abdominal lymph nodes in end-stage cirrhosis: CT-histopathologic correlation in 507 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21349785" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Lymph node metastasis diagnosed by EUS-FNA in four cases with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12874516" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Evaluation of optimal timing of arterial phase imaging for the detection of hypervascular hepatocellular carcinoma by using triple arterial phase imaging with multidetector-row helical computed tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15671002" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Hepatocellular carcinoma: role of unenhanced and delayed phase multi-detector row helical CT in patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12563152" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hepatocellular carcinoma: detection with triple-phase multi-detector row helical CT in patients with chronic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11351179" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14512891" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16357395" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31062483" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (&lt;3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31372783" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30257054" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Validation of Liver Imaging Reporting and Data System 2017 (LI-RADS) Criteria for Imaging Diagnosis of Hepatocellular Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22948836" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Improved long-term survival after major resection for hepatocellular carcinoma: a multicenter analysis based on a new definition of major hepatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22903563" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Resection of large hepatocellular carcinoma (≥10 cm): a unique western perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23188527" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Long-term outcome after liver resection for hepatocellular carcinoma larger than 10 cm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19106686" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11896101" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Simplified staging for hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8385442" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17690940" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Long term outcome and prognostic factors for large hepatocellular carcinoma (10 cm or more) after surgical resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11438270" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Hepatic resection for large hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11995486" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Hepatic resection for hepatocellular carcinoma in diameter of&gt;or = 10 cm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9876069" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Surgical treatment and outcome in patients with a hepatocellular carcinoma greater than 10 cm in diameter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14597446" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10 cm: two decades of experience at Chang Gung memorial hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16196045" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Outcome of partial hepatectomy for large (&gt;10 cm) hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22903402" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Impact of hepatectomy for huge solitary hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23179993" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Microvascular invasion does not predict long-term survival in hepatocellular carcinoma up to 2 cm: reappraisal of the staging system for solitary tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31058694" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effect of Microvascular Invasion Risk on Early Recurrence of Hepatocellular Carcinoma After Surgery and Radiofrequency Ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27550624" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Long-term survival of patients undergoing liver resection for very large hepatocellular carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36896301" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Does size matter for resection of giant versus non-giant hepatocellular carcinoma? A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30594407" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Liver resection is justified for multinodular hepatocellular carcinoma in selected patients with cirrhosis: A multicenter analysis of 1,066 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29258719" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31024207" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Rupture of Hepatocellular Carcinoma: A Review of Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22864567" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Management of spontaneously ruptured hepatocellular carcinoma and hemoperitoneum manifested as acute abdomen in the emergency room.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20395862" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cohort study of the survival benefit of resection for recurrent hepatic and/or pulmonary metastases after primary hepatectomy for colorectal metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15048744" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Influence of laparoscopy on postoperative recurrence and survival in patients with ruptured hepatocellular carcinoma undergoing hepatic resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11533094" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Management of spontaneous rupture of hepatocellular carcinoma: single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11978996" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Management of spontaneous rupture of liver tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12143205" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Staged hepatectomy following arterial embolization for ruptured hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12190677" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Spontaneous tumour rupture and prognosis in patients with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22648995" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Liver resection for complicated hepatocellular carcinoma: challenges but opportunity for long-term survivals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23478524" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37154926" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Prognosis of spontaneously ruptured hepatocellular carcinoma: a propensity score matching study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9530543" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Practical considerations in the treatment of hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33294830" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14609867" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : One thousand fifty-six hepatectomies without mortality in 8 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20822741" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Perioperative management of hepatic resection toward zero mortality and morbidity: analysis of 793 consecutive cases in a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12368667" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26328026" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Strategies to increase the resectability of hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16795964" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Resectability of hepatocellular carcinoma: evaluation of 333 consecutive cases at a single hepatobiliary specialty center and systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8210909" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Surgery for small liver cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15754094" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34505035" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30326907" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Ability of the ALBI grade to predict posthepatectomy liver failure and long-term survival after liver resection for different BCLC stages of HCC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34666694" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Preoperative ALBI grade predicts the outcomes in non-B non-C HCC patients undergoing primary curative resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11167863" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Portal vein embolization: rationale, technique and future prospects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12560779" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Portal vein embolization before right hepatectomy: prospective clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27593595" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Measurement of liver function using hepatobiliary scintigraphy improves risk assessment in patients undergoing major liver resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19937195" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Assessment of future remnant liver function using hepatobiliary scintigraphy in patients undergoing major liver resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19937195" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Assessment of future remnant liver function using hepatobiliary scintigraphy in patients undergoing major liver resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22009385" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Value of hepatic venous pressure gradient measurement before liver resection for hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10094953" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Preoperative portal vein embolization: an audit of 84 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18156923" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Preoperative portal vein embolization for major liver resection: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21069467" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization only before major hepatectomy for patients with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25158914" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Remnant growth rate after portal vein embolization is a good early predictor of post-hepatectomy liver failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19303988" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16779884" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7881929" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16797156" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10947016" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19408012" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8678616" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8661839" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9845635" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19226530" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15249411" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27283892" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34095718" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Oncological benefits of portal vein embolization for patients with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37024339" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Optimizing the future liver remnant: Portal vein embolization, hepatic venous deprivation, and associating liver partition and portal vein ligation for staged hepatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18304505" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : A technique for safely teaching major hepatectomy to surgical residents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21465322" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Anatomical right posterior sectionectomy: a further expansion of the ultrasound-guided compression technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1846986" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : A new method for mapping hepatic subsegment: counterstaining identification technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24159592" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Intraoperative ultrasound in patients with hepatocellular carcinoma: from daily practice to future trends.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35332767" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Future remnant liver optimization: preoperative assessment, volume augmentation procedures and management of PVE failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22407377" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Equivalent outcomes after anatomical and non-anatomical resection of small hepatocellular carcinoma in patients with preserved liver function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29751946" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Anatomic versus non-anatomic resection for hepatocellular carcinoma: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25847111" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Anatomical versus non-anatomical resection for hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31898106" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Is It Just a Matter of Surgical Extension to Achieve the Cure of Hepatocarcinoma? A Meta-Analysis of Propensity-Matched and Randomized Studies for Anatomic Versus Parenchyma-Sparing Liver Resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29861336" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Long-term oncologic results of anatomic vs. parenchyma-sparing resection for hepatocellular carcinoma. A propensity score-matching analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16858181" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29209133" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Anterior vs conventional approach right hepatic resection for large hepatocellular carcinoma: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36846068" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Liver hanging maneuver is suitable in major hepatectomy for liver malignancies over 5 cm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12679915" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Right trisectionectomy for primary liver cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12520572" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Risk factors for perioperative morbidity and mortality after extended hepatectomy for hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11192922" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Extended hepatic resection: a 6-year retrospective study of risk factors for perioperative mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18926451" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Mesohepatectomy as an option for the treatment of central liver tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10930479" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Mesohepatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27272270" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Central Hepatectomy versus Extended Hepatectomy for Malignant Tumors: A Propensity Score Analysis of Postoperative Complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36600282" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Central hepatectomy versus major hepatectomy for patients with centrally located hepatocellular carcinoma: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33646429" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Central Hepatectomy Versus Major Hepatectomy for Centrally Located Hepatocellular Carcinoma: A Propensity Score Matching Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36980626" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Risk Factors of Complications from Central Bisectionectomy (H458) for Hepatocellular Carcinoma: A Multi-Institutional Single-Arm Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36849753" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Asia-Pacific multicentre randomized trial of laparoscopic versus open major hepatectomy for hepatocellular carcinoma (AP-LAPO trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30363804" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : The current role of laparoscopic resection for HCC: a systematic review of past ten years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30390167" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : A Systematic Review and Meta-Analysis Comparing the Short- and Long-Term Outcomes for Laparoscopic and Open Liver Resections for Hepatocellular Carcinoma: Updated Results from the European Guidelines Meeting on Laparoscopic Liver Surgery, Southampton, UK, 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25009403" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Laparoscopic vs open approach to resection of hepatocellular carcinoma in patients with known cirrhosis: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35884421" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Does Robotic Liver Surgery Enhance R0 Results in Liver Malignancies during Minimally Invasive Liver Surgery?-A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32762406" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Robotic versus conventional laparoscopic liver resections: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14631225" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Resection prior to liver transplantation for hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23741309" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Perioperative allogenenic blood transfusion is associated with worse clinical outcomes for hepatocellular carcinoma: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15966217" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Comparative analysis of postoperative morbidity according to type and extent of hepatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19387322" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Predictors of survival after resection of early hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11981219" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Preoperative predictors of survival after resection of small hepatocellular carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30377911" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Early Morbidity and Mortality after Minimally Invasive Liver Resection for Hepatocellular Carcinoma: a Propensity-Score Matched Comparison with Open Resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29363237" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Liver resection for hepatocellular carcinoma: personal experiences in a series of 1330 consecutive cases in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27797420" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Survival analysis after liver resection for hepatocellular carcinoma: A consecutive cohort of 1002 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17481498" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16648507" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35901605" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Two decades of liver resection with a multidisciplinary approach in a single institution: What has changed? Analysis of 1409 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23132620" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Liver resection for hepatocellular carcinoma in patients without cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29947980" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Liver Resection for Hepatocellular Carcinoma in Patients with Renal Dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33711132" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Laparoscopic and open liver resection for hepatocellular carcinoma with Child-Pugh B cirrhosis: multicentre propensity score-matched study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36471191" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Surgical Outcomes for Hepatocellular Carcinoma in Patients with Child-Pugh Class B: a Retrospective Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2154902" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Can hepatic failure after surgery for hepatocellular carcinoma in cirrhotic patients be prevented?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32993315" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Risk Factors for and Outcomes of Intraoperative Blood Loss in Liver Resection for Hepatocellular Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27684875" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Risk factors for early mortality after hepatectomy for hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31276196" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Impact of postoperative infective complications on long-term survival after liver resection for hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17419257" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Liver resection for HCC: analysis of causes and risk factors linked to postoperative complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35534739" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : A scoring system to predict the risk of major complications after laparoscopic liver resection in elderly patients with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35316229" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : A predictive model incorporating inflammation markers for high-grade surgical complications following liver resection for hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26459723" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : A three-factor preoperative scoring model predicts risk of recurrence after liver resection or transplantation in hepatocellular carcinoma patients with preserved liver function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27084430" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : A Global Risk Score (GRS) to Simultaneously Predict Early and Late Tumor Recurrence Risk after Resection of Hepatocellular Carcinoma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
